Previous close | 3.3600 |
Open | N/A |
Bid | 0.4500 |
Ask | 4.4000 |
Strike | 390.00 |
Expiry date | 2024-08-16 |
Day's range | 3.3600 - 3.3600 |
Contract range | N/A |
Volume | |
Open interest | N/A |
As the Nasdaq and S&P 500 continue to set records, reflecting a robust appetite for growth among investors, it's an opportune time to explore companies where high insider ownership aligns closely with corporate ambitions and investor interests. In this context, firms with substantial insider stakes can be particularly compelling, as they often signal confidence from those who know the company best.
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss. Other companies working on MASH candida